Trump announces all 50 states join Medicaid drug pricing program

All 50 U.S. states will now participate in a Medicaid drug pricing program using Most Favored Nation pricing, affecting pharmaceutical rebate structures and state healthcare budgets. The White House projects $64.3 billion in Medicaid savings over ten years and $600 billion across all pricing initiatives, contingent on participation by 26 major manufacturers covering 90% of the branded U.S. market. Implementation will influence drug pricing benchmarks across federal and state programs ahead of November 2026 midterm elections. Cost-benefit verification depends on public disclosure of agreement terms; the lack of published details currently prevents independent assessment of savings claims.